10-Q: Vycor Medical Reports First Quarter 2024 Results Amidst Going Concern Uncertainty

Sentiment:

Quarterly Report 15 May 2024 1:03 PM

Vycor Medical's Q1 2024 results show a net loss and a working capital deficiency, raising concerns about the company's ability to continue as a going concern.

Capital raiseThe company believes it may not have sufficient cash to meet its various cash needs through May 31, 2025 unless the Company is able to obtain additional cash from the issuance of debt or equity securities.The company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all.

Worse than expectedThe company's net loss of $30,608 is significantly worse than the net income of $6,862 reported in the same period last year.The company's revenue decreased by 7% year-over-year, indicating a decline in sales performance.The company's working capital deficiency of $3,668,137 raises concerns about its financial stability.

Summary

Vycor Medical reported a net loss of $30,608 for the three months ended March 31, 2024, compared to a net income of $6,862 for the same period in 2023.
The company's revenue decreased by 7% to $336,968 in Q1 2024 from $360,994 in Q1 2023.
Vycor Medical's working capital deficiency was $3,668,137 as of March 31, 2024, which includes $3,133,701 in related party liabilities.
The company's cash balance decreased to $43,857 as of March 31, 2024, from $57,291 at the end of 2023.
The company has a term note for $300,000 to EuroAmerican Investment Corp. with accrued interest of $484,866, due March 31, 2025, and it is uncertain if this will be extended.
Vycor Medical is executing a plan to reduce cash operating losses and generated cash operating income for the three months ended March 31, 2024.
The company may need to seek additional equity or debt funding to meet its cash needs through May 31, 2025.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with a net loss, declining revenue, and a significant working capital deficiency. The company's ability to continue as a going concern is in doubt, and there is a reliance on related party funding. While there are some positive aspects, the overall sentiment is negative.

Positives

Vycor Medical is executing a plan to reduce cash operating losses.
The company generated cash operating income for the three months ended March 31, 2024.
The company is focused on increasing market penetration in the US and international growth.
The company has completed the international roll-out of the VBAS AC model range by the end of 2023.
The company is exploring further integration of VBAS with neuronavigation and other complementary technologies.

Negatives

The company experienced a 7% decrease in revenue compared to the same period last year.
The company reported a net loss of $30,608 for the quarter.
The company has a significant working capital deficiency of $3,668,137.
The company's cash balance is low at $43,857.
There is substantial doubt about the company's ability to continue as a going concern.
The company is reliant on working capital funding from its largest shareholder, Fountainhead, with no guarantee of continued support.

Risks

The company's ability to continue as a going concern is in doubt due to its working capital deficiency and ongoing losses.
The company may not be able to obtain additional funding on acceptable terms or at all.
Failure to secure additional funding could lead to delays or curtailment of product development and commercialization, or even cessation of operations.
The company is reliant on a term note to EuroAmerican, which may not be extended beyond March 31, 2025.
The company's largest shareholder may not continue to provide working capital funding.
The company's internal controls are not fully effective due to the lack of a functioning audit committee with independent members.

Future Outlook

The company believes it may not have sufficient cash to meet its various cash needs through May 31, 2025 unless it obtains additional cash from the issuance of debt or equity securities. The company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all.

Management Comments

The company is continuing to execute on a plan to achieve revenue growth and a reduction in annual cash operating losses.
Management is open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.

Industry Context

The medical device industry is competitive, and Vycor Medical operates in the niche areas of neurosurgery and vision rehabilitation. The company's performance is affected by market penetration, regulatory approvals, and the adoption of its technologies by medical professionals. The company's strategy of partnering with entities in selected geographies for NovaVision is a common approach for companies with broad product ranges and limited resources.

Comparison to Industry Standards

It is difficult to make a direct comparison to industry standards without knowing the specific peer group of Vycor Medical.
However, the company's negative net income and working capital deficiency are concerning and suggest that it is underperforming compared to many established medical device companies.
The company's reliance on related party funding is also a potential red flag, as it may indicate a lack of access to traditional financing sources.
Companies like Medtronic and Stryker, which are leaders in the medical device industry, typically have strong balance sheets and consistent profitability.
Smaller companies in the medical device space often face challenges in achieving profitability and securing funding, and Vycor Medical's situation is not uncommon for companies in this category.
The company's focus on minimally invasive procedures aligns with a broader trend in the medical device industry, but its financial performance needs to improve to capitalize on this trend.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Material Weakness	A material weakness occurred as of April 1, 2021 with the resignation of the independent members of the Company's Audit Committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.	2021-04-01	The lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors, results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Legal Proceedings

As of May 15, 2024, the company was not a party to any material litigation, claim or suit whose outcome could have a material effect on its financial statements.

Related Party Transactions

Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at March 31, 2024, 62.3 % of the Company's Common Stock and 69.7 % of the Company's Series D Preferred Stock.
Peter Zachariou owns 0.15 % of the Company's Common Stock and 25.7 % of the Company's Series D Preferred Stock.
Adrian Liddell, Chairman is a consultant to Fountainhead.
During each of the three months ended March 31, 2024 and 2023, the Company accrued an aggregate of $162,185 of Preferred D Stock dividends, of which $113,019 was regarding Fountainhead and $41,693 was regarding Peter Zachariou.
Total accrued Preferred D Stock dividends at March 31, 2024 and December 31, 2023 was $2,432,775 and $2,270,590, respectively, of which $1,695,280 and $1,582,260 respectively, was regarding Fountainhead and $625,394 and $583,701, respectively, was regarding Peter Zachariou.
During the three months ended March 31, 2024 and 2023 the Company accrued interest on related party loans of $12,031 and $12,343, respectively.

Stakeholder Impact

Shareholders face significant risk due to the company's financial instability and the uncertainty of its future operations.
Employees may be concerned about job security given the company's going concern issues.
Customers may be concerned about the company's ability to continue providing products and services.
Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

The company will continue to execute on a plan to achieve revenue growth and a reduction in annual cash operating losses.
The company will continue to work with neuronavigation companies to seek ways to further integrate the VBAS with neuronavigation.
The company will explore with neurosurgeons and focus groups additional selected development work targeted at increasing the ease and applicability of our products to additional common procedures.
The company may consider seeking additional equity or debt funding.

Key Dates

Date	Description
2011-03-25	Date of the original term note issued to EuroAmerican Investment Corp.
2011-06-11	Original due date of the term note to EuroAmerican Investment Corp.
2012-06-30	Date of preliminary tax assessment for NovaVision German subsidiary.
2018-01-31	Date of amendment agreement with EuroAmerican Investments regarding its $300,000 loan note.
2018-03-26	Start date of promissory notes issued to Fountainhead Capital Management Limited.
2018-06-25	Date of promissory notes issued to Peter Zachariou.
2020-04-01	Date of resignation of independent members of the Company's Audit Committee.
2020-06-30	Effective date of closure of NovaVision German office.
2020-07-07	Date the company was granted a $150,000 loan under the Economic Injury Disaster Loan Program.
2021-03-30	Date of Consulting Agreement with Ricardo J. Komotar, M.D.
2022-11-17	End date of promissory notes issued to Fountainhead Capital Management Limited.
2023-04-01	Date of issuance of 101,663 shares of Common Stock to Ricardo Komotar.
2023-08-31	Original termination date of the office lease.
2024-03-31	End of the fiscal quarter for this report and maturity date of the EuroAmerican term note.
2024-05-15	Date of the report and shares outstanding.
2026-12-31	New termination date of the office lease.

Keywords

Vycor Medical, financial results, going concern, working capital, net loss, revenue, medical devices, neurosurgery, NovaVision, debt, Fountainhead, cash flow

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.